GlassScriptPhysician profile
Kevin M Doyle
NPI 1972573608
$3,700.83
in general payments reported to CMS, 2019-2025
19 companies · $2,220 in 2025
The $2,220 reported for 2025 was more than what 90% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $62.07 · 2021: $138 · 2022: $311 · 2023: $261 · 2024: $244 · 2025: $2,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,800 · Food and Beverage: $891 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,800.00 |
| Food and Beverage | $891.19 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $1,800.00 | 2025 | Bronchoscope |
| Acclarent, INC | $254.83 | 2019-2024 | Acclarent Aera |
| Alk-Abello, INC | $238.50 | 2020-2023 | Odactra |
| Regeneron Healthcare Solutions, INC. | $216.88 | 2019-2023 | Dupixent |
| Aerin Medical INC. | $208.78 | 2019-2023 | |
| Glaxosmithkline, LLC. | $206.79 | 2023-2025 | Nucala, Trelegy Ellipta |
| Intersect Ent, INC. | $169.11 | 2019 | |
| Medtronic, INC. | $133.45 | 2024 | Nuvent |
| Integra Lifesciences Corporation | $105.10 | 2023-2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Genzyme Corporation | $67.02 | 2023 | |
| Smith+Nephew, INC. | $62.09 | 2020-2025 | Tula |
| Organogenesis INC. | $40.41 | 2022 | |
| Optinose US, INC. | $39.35 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $38.79 | 2025 | Neffy |
| Amgen INC. | $34.00 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $26.40 | 2022-2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $23.46 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.73 | 2025 | Tezspire |
| Stryker Corporation | $17.14 | 2025 | Audion Et Dilation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.